MCC950 has been shown to be effective for the treatment of CAPS in mice harboring activating Nlrp3 mutations (Coll et al., 2015) and in mouse models of dermal and airway inflammation (Primiano et al., 2016). Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.